In another meta‐analysis, the risk of pneumonitis was significantly increased with anti‐PD‐1/PD‐L1 therapies in TNBC (odds ratio: 2.52; 95% CI: 1.02–6.26).33 Here, CD274 is linked to pneumonitis.